Maze Therapeutics (MAZE) Common Equity (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Common Equity data on file, last reported at $341.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 16.99% year-over-year to $341.7 million; the trailing twelve-month figure through Mar 2026 stood at $341.7 million (up 16.99% YoY), and the FY2025 full-year result was $355.0 million, up 214.07% from the prior year.
• Common Equity declined to $341.7 million in Q1 2026, from $355.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $379.4 million in Q3 2025 to a low of -$403.7 million in Q1 2024.
• A 3-year average of $41.0 million and a median of $262.2 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 233.35% in 2025 and gained 16.99% in 2026, its largest moves.
• Tracing MAZE's Common Equity over 3 years: stood at -$311.2 million in 2024, then soared by 214.07% to $355.0 million in 2025, then dropped by 3.74% to $341.7 million in 2026.
• Business Quant data shows MAZE's Common Equity at $341.7 million in Q1 2026, $355.0 million in Q4 2025, and $379.4 million in Q3 2025.